GSK’s profit rose on better-than-expected performance of HIV, cancer and asthma treatments, offsetting lower vaccine demand in the U.S. GSK plans to bring five new specialty medicines to market this ...

GSK's 2024 results are strong, with a promising shift toward specialty medicines, particularly in HIV, respiratory conditions, and cancer, driving long-term growth. Key drugs Blenrep and Depemokimab ...

The funding will move early-stage research to the next level, to find new medicines for diseases such as TB, malaria, Leishmaniasis and sleeping sickness. Scientists from around the world will work in ...

GlaxoSmithKline ((GSK)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...

GSK GSK0.30%increase; green up pointing triangle raised its sales and earnings forecasts for the year after its specialty medicines business helped lift sales in the third quarter, the last reporting ...

GSK posted higher profit as sales for its specialty treatments including HIV, cancer and asthma beat expectations, offsetting lower vaccine sales on weak demand in the U.S. GSK plans to bring five new ...

GSK said it is confident of achieving the top end of its full-year guidance after posting an increase in sales and profit for the second quarter, mainly driven by the strong performance of its ...